Viral Clearance Market - Global Forecasts to 2023 - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023” report has been added to ResearchAndMarkets.com’s offering.

The global viral clearance market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period.

Growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and the high incidence and large economic burden of chronic diseases are expected to drive the growth of the viral clearance market. However, the high-cost requirements for drug development may hamper the pace of activity in this sector, and consequently the adoption of viral clearance practices.

On the basis of application, the global viral clearance market is segmented into recombinant proteins, blood and blood products, vaccines, and other applications. The other applications segment is expected to grow at the highest CAGR during the forecast period owing to the increasing use of cellular therapies in the treatment of cancer, hematologic malignancies, autoimmune disorders, and damaged tissue; growing industry focus on stem cell research; increasing awareness about stem cell therapies; and the use of tissue-based therapies to treat various diseases related to the kidneys, liver, heart, and lungs.

On the basis of method, the global viral clearance market is segmented into two broad categories - viral removal and viral inactivation. The viral removal segment is estimated to account for the largest share of the global viral clearance market in 2018. This segment is also expected to grow at the highest rate during the forecast period. The large share of this market segment is primarily attributed to the growth of biopharmaceutical R&D activities; high acceptance of this method; and the accuracy, speed, and flexibility provided by the method in life sciences research.

Asia Pacific is expected to witness the highest growth from 2018 to 2023, owing to increase in generics development and manufacturing, surge in Chinese funding for medical research, and presence of large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Viral Clearance Market, By Application

7 Viral Clearance Market, By End User

8 Viral Clearance Market, By Method

9 Viral Clearance Market, By Region

10 Competitive Landscape

11 Company Profiles

Charles River Laboratories International Inc. Merck KGaA Wuxi Biologics Kedrion S.p.A. Vironova Biosafety Texcell Clean Cells BSL BIOSERVICE Scientific Laboratories Munich GmbH ViruSure GmbH For more information about this report visit https://www.researchandmarkets.com/research/768xmq/viral_clearance?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005501/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Disease Testing



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 04:58 AM/DISC: 09/25/2018 04:57 AM


Update hourly